Mazdutide (10mg Vial) Dosage Protocol
GLP-1 / glucagon dual agonist for weight management — research/educational dosing reference.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure Mazdutide · 10 mg
Dosing & Reconstitution Guide
A practical dilution with accurate once-weekly dosing, step by step
Standard / Gradual Titration (3.0 mL = ~3.33 mg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg vial → final concentration ~3.33 mg/mL (3,333 mcg/mL).
Typical weekly range: 2.5–6 mg once weekly, raised gradually with stepwise titration.
Easy measuring: At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe. The 2.5 mg maintenance dose reads at 75 units; a 5 mg dose reads at 150 units (1.50 mL).
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Why Mazdutide draws research interest
These are the directions researchers and the peptide community most often explore Mazdutide for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Weight management
Studied as a GLP-1/glucagon dual agonist for body-weight reduction; approved in China (2025) for weight management, not FDA-approved.
Glycemic control
Studied in type 2 diabetes research for effects on blood glucose and HbA1c; approved in China (2025) for glycemic control, not FDA-approved.
Hepatic fat / liver
Explored in research on hepatic fat, where its glucagon-receptor arm is investigated for effects on liver fat content.
Energy expenditure
Researched for the glucagon component's role in energy expenditure and metabolic rate; investigational, preclinical and clinical.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
Mazdutide (IBI362 / LY3305677) is a long-acting dual GLP-1 and glucagon receptor agonist developed for chronic weight management and type-2-diabetes glycemic control[1][2]. Phase 2 and phase 3 trials have reported substantial weight loss (roughly 6–14% over 24–48 weeks) with mostly mild gastrointestinal side effects[2][3][5]. This educational page outlines a once-weekly subcutaneous approach with a dilution chosen so doses land on easy-to-read insulin-syringe marks. Mazdutide is approved in China (NMPA, June 2025) but is investigational and not FDA- or EMA-approved elsewhere — presented for research and educational use only.
Add 3.0 mL bacteriostatic water to one 10 mg vial → ~3.33 mg/mL (3,333 mcg/mL), the standard dilution for clear unit measurements.
2.5–6 mg once weekly with gradual stepwise titration; advanced research protocols may reach ~10 mg/week.
At ~3.33 mg/mL, 1 unit ≈ 33.3 mcg; 2.5 mg ≈ 75 units and 5 mg ≈ 150 units on a U-100 syringe.
Lyophilized: store at −20 °C (−4 °F); once reconstituted, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the solution.
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Frequency: one subcutaneous injection once weekly, titrating up as tolerated. This stepwise schedule mirrors clinical-trial protocols designed to improve gastrointestinal tolerability[1][2]. A 5 mg dose reads at just 150 units (1.50 mL) — if you prefer an even smaller injection volume, use the higher-concentration advanced dilution below.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial's inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don't shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
Advanced / High-Dose Protocol (2.0 mL = 5.0 mg/mL)
Reconstituting with only 2.0 mL gives a higher concentration (5.0 mg/mL, so 1 unit = 50 mcg), reducing the injection volume for larger doses.
High-dose schedules (7.5–10 mg weekly) have only been explored in early-phase research and demand careful monitoring. Doses above ~6 mg increase the likelihood of gastrointestinal side effects. For any dose needing more than 3.0 mL of total volume, split it into two separate injections at different sites.
Supplies Needed
Quantities below assume an 8–16 week once-weekly course with gradual titration to a 5 mg maintenance dose.
A 10 mg vial covers about one week at the maintenance dose; titration uses less early on, so plan a little over one vial per maintenance week.
- 8 weeks: ~3 vials
- 12 weeks: ~5 vials
- 16 weeks: ~7 vials
One syringe per weekly injection; larger maintenance volumes may use a 3 mL syringe or be split.
- Per injection: 1 syringe
- 8 weeks (once weekly): ~8 syringes
- 16 weeks (once weekly): ~16 syringes
Use ~3.0 mL per 10 mg vial for standard reconstitution.
- 8 weeks (6 vials): ~18 mL → 2 bottles
- 16 weeks (14 vials): ~42 mL → 5 bottles
One for the vial stopper + one for the injection site each week.
- Per injection: 2 swabs
- 8–16 weeks (once weekly): ~16–32 swabs → 1 box
Protocol Overview
A concise summary of the once-weekly regimen, drawn from published clinical-trial protocols.
- ▪Goal: Support chronic weight management and glycemic control through dual GLP-1 / glucagon receptor activation[2][3].
- ▪Schedule: Once-weekly subcutaneous injections; trials have run from 12 to 48 weeks.
- ▪Dose Range: 2.5–6 mg weekly with gradual titration; advanced research protocols may reach ~10 mg.
- ▪Reconstitution: 3.0 mL per 10 mg vial gives ~3.33 mg/mL; use 2.0 mL for a higher concentration if needed.
- ▪Storage: Keep the dry vial frozen at −20 °C (−4 °F); once mixed, refrigerate at 2–8 °C and discard after ~28 days.
Dosing Protocol
A suggested weekly titration approach based on common clinical-trial reference doses.
- ▪Start: Begin at 2.5 mg once weekly for the first 4 weeks to establish tolerability.
- ▪Titrate: Step up to 5 mg weekly at week 5 and hold for the remainder of the protocol.
- ▪Target: Reach a 5–6 mg weekly maintenance dose; advanced research protocols may go higher.
- ▪Cycle Length: A minimum of ~8 weeks; clinical evidence supports 12–48 week courses.
- ▪Timing: Inject on the same day each week and rotate injection sites systematically.
Storage Instructions
Correct storage is what preserves the peptide's stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[7].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won't form, and keep the solution clear of heat and direct light.
- ▪Discard: Dispose of reconstituted vials after 28 days or if cloudiness or particulates appear.
Important Notes
Practical points that keep weekly administration safe and consistent.
- ▪Sterile technique: Use a fresh sterile insulin syringe each week and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms each week to reduce local irritation and lipohypertrophy[8][10].
- ▪Split large volumes: For any dose needing more than ~3 mL of total volume, divide it into two injections at separate sites for comfort and absorption.
- ▪Warm before drawing: Let the reconstituted vial reach room temperature before withdrawing the dose to reduce viscosity.
- ▪Regulatory note: Mazdutide is approved in China for weight management and type-2 diabetes (NMPA, June 2025) but is investigational and not FDA- or EMA-approved elsewhere.
How This Works
Mazdutide (IBI362 / LY3305677) is a long-acting dual agonist that activates both the GLP-1 and the glucagon receptors[2][6]. The GLP-1 arm curbs appetite and slows gastric emptying, while the glucagon arm raises energy expenditure — together producing weight loss and improved glycemic control.
This dual mechanism distinguishes mazdutide from single-target GLP-1 agonists such as semaglutide. Phase 2 studies reported roughly 6.7–11.3% body-weight reduction at 3–6 mg weekly over 24 weeks[2], and a 48-week phase 3 trial described sustained weight loss of about 11–14% with 4–6 mg weekly maintenance[3].
In people with type 2 diabetes, mazdutide achieved meaningful HbA1c reductions (around 1.7%) alongside roughly 7% weight loss[4]. Its extended half-life enables convenient once-weekly dosing with steady pharmacologic exposure.
Approval status: China's NMPA approved mazdutide in June 2025 for chronic weight management and for glycemic control in type 2 diabetes. Outside China it remains investigational and is not FDA- or EMA-approved; the dosing here is presented for research and educational purposes only.
Lifestyle Factors
Habits that may support outcomes alongside the protocol.
- ▪Nutrition: Keep a balanced, nutrient-dense diet with adequate protein to preserve lean mass during weight loss.
- ▪Activity & rest: Combine resistance training with aerobic exercise to protect muscle and support metabolic adaptation.
- ▪Sleep: Aim for 7–9 hours to support adherence and hormonal balance.
- ▪Hydration & electrolytes: Stay well hydrated and watch electrolyte intake, especially during early titration when GI effects are more likely.
Potential Benefits & Side Effects
Observations drawn from clinical-trial evidence; individual results vary.
Potential Benefits
- ▪Significant weight loss: 6–14% body-weight reduction over 24–48 weeks in obesity trials[2][3][5].
- ▪Glycemic improvement: Meaningful HbA1c reductions (~1.7%) in type-2-diabetes populations[4].
- ▪Metabolic effects: Reported improvements in lipid profiles and glucose control alongside weight loss.
- ▪Convenient dosing: Once-weekly administration can improve adherence versus daily regimens.
Common Side Effects
- ▪Gastrointestinal effects: Nausea, vomiting, diarrhea and constipation are most common — usually mild to moderate and easing with continued use[5].
- ▪Injection-site reactions: Mild redness, swelling or discomfort can occur; rotating sites helps.
- ▪Titration matters: Gradual dose escalation improves tolerability and reduces discontinuation[1][2].
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[8][10].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully.
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[8].
- ▪Skip aspiration for subcutaneous shots — it isn't needed[8].
- ▪Press the plunger slowly and steadily until it's fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each week to prevent irritation and lipohypertrophy[8].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for Mazdutide (10 mg).
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
EClinicalMedicine (PubMed)Phase 1b trial: safety and efficacy of mazdutide 9–10 mg in Chinese adults with overweight or obesity.
- 2
Nature CommunicationsPhase 2 randomized controlled trial of mazdutide in Chinese adults with overweight or obesity.
- 3
New England Journal of MedicinePhase 3 trial: once-weekly mazdutide in Chinese adults with obesity or overweight (48-week results).
- 4
Diabetes Care (PubMed)Phase 2 trial: efficacy and safety of mazdutide in Chinese patients with type 2 diabetes.
- 5
Frontiers in EndocrinologySystematic review and meta-analysis of mazdutide for weight loss in diabetic and non-diabetic patients.
- 6
International Journal of Obesity (Nature)Review of the pipeline for future obesity medications, including GLP-1 / glucagon dual agonists such as mazdutide.
- 7
Bachem Peptide Technical GuideHandling and storage guidelines for peptides, both lyophilized and in solution.
- 8
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 9
NMPA / China Regulatory NoticeChina NMPA approval of mazdutide (June 2025) for chronic weight management and type-2-diabetes glycemic control.
- 10
CDCSubcutaneous injection technique: angle, site selection and no-aspiration guidance.
Mazdutide — frequently asked questions
How do I reconstitute a 10 mg vial of Mazdutide?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to Mazdutide?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store Mazdutide after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of Mazdutide provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is Mazdutide approved for human use?
No. Mazdutide is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.